The 36-month beta value for BEAM is also noteworthy at 1.88. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for BEAM is 68.41M, and at present, short sellers hold a 19.26% of that float. The average trading volume of BEAM on May 09, 2024 was 1.53M shares.
BEAM) stock’s latest price update
Beam Therapeutics Inc (NASDAQ: BEAM) has seen a decline in its stock price by -1.29 in relation to its previous close of 22.53. However, the company has experienced a 2.30% gain in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-05-08 that Beam Therapeutics (BEAM) reports mixed first-quarter results. The company remains focused on pipeline development.
BEAM’s Market Performance
Beam Therapeutics Inc (BEAM) has experienced a 2.30% rise in stock performance for the past week, with a -24.15% drop in the past month, and a -19.33% drop in the past quarter. The volatility ratio for the week is 5.08%, and the volatility levels for the past 30 days are at 5.38% for BEAM. The simple moving average for the last 20 days is -6.09% for BEAM stock, with a simple moving average of -17.59% for the last 200 days.
Analysts’ Opinion of BEAM
Many brokerage firms have already submitted their reports for BEAM stocks, with JP Morgan repeating the rating for BEAM by listing it as a “Overweight.” The predicted price for BEAM in the upcoming period, according to JP Morgan is $40 based on the research report published on January 29, 2024 of the current year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see BEAM reach a price target of $35. The rating they have provided for BEAM stocks is “Neutral” according to the report published on December 15th, 2023.
Jefferies gave a rating of “Hold” to BEAM, setting the target price at $30 in the report published on December 08th of the previous year.
BEAM Trading at -27.10% from the 50-Day Moving Average
After a stumble in the market that brought BEAM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -55.07% of loss for the given period.
Volatility was left at 5.38%, however, over the last 30 days, the volatility rate increased by 5.08%, as shares sank -17.81% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -50.65% lower at present.
During the last 5 trading sessions, BEAM rose by +2.30%, which changed the moving average for the period of 200-days by -29.51% in comparison to the 20-day moving average, which settled at $23.44. In addition, Beam Therapeutics Inc saw -18.30% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BEAM starting from Simon Amy, who sale 16,530 shares at the price of $30.54 back on Apr 02 ’24. After this action, Simon Amy now owns 70,060 shares of Beam Therapeutics Inc, valued at $504,851 using the latest closing price.
Evans John M., the CEO of Beam Therapeutics Inc, sale 18,102 shares at $32.13 during a trade that took place back on Apr 01 ’24, which means that Evans John M. is holding 1,058,343 shares at $581,617 based on the most recent closing price.
Stock Fundamentals for BEAM
Current profitability levels for the company are sitting at:
- -0.47 for the present operating margin
- 0.93 for the gross margin
The net margin for Beam Therapeutics Inc stands at -0.32. The total capital return value is set at -0.14. Equity return is now at value -16.09, with -10.01 for asset returns.
Based on Beam Therapeutics Inc (BEAM), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -0.86. The debt to equity ratio resting at 0.18. The interest coverage ratio of the stock is -5.1.
Currently, EBITDA for the company is -156.47 million with net debt to EBITDA at 1.54. When we switch over and look at the enterprise to sales, we see a ratio of 4.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.99.
Conclusion
In summary, Beam Therapeutics Inc (BEAM) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
